Liver Disease – Society of Cannabis Clinicians https://www.cannabisclinicians.org Educating Healthcare Professionals about the Medical Use of Cannabis Sun, 28 May 2023 00:46:09 +0000 en-US hourly 1 https://wordpress.org/?v=6.2.3 https://www.cannabisclinicians.org/wp-content/uploads/2020/07/cropped-scc-flavicon-32x32.png Liver Disease – Society of Cannabis Clinicians https://www.cannabisclinicians.org 32 32 Marijuana use is inversely associated with liver steatosis detected by transient elastography in the general United States population in NHANES 2017–2018: A cross-sectional study https://www.cannabisclinicians.org/2023/05/27/marijuana-use-is-inversely-associated-with-liver-steatosis-detected-by-transient-elastography-in-the-general-united-states-population-in-nhanes-2017-2018-a-cross-sectional-study/ Sun, 28 May 2023 00:46:09 +0000 https://www.cannabisclinicians.org/?p=28699 Whole-plant medical cannabis (MC) products are widely used for controlling symptoms associated with Parkinson's disease (PD). Despite its widespread use, few studies have investigated the long-term impact of MC on the progression of PD or its safety profile. This study examined the effects of MC on PD in a real-life setting. A retrospective case-control study of 152 idiopathic PD patients (mean age 69.1 ± 9.0 years), followed at the Sheba Medical Center Movement Disorders Institute (SMDI) from 2008 to 2022 was conducted. Seventy-six patients who used licensed whole-plant medical cannabis (MC) for at least a year were compared to a matched group who did not receive MC in terms of their Levodopa Equivalent Daily Dose (LEDD), Hoehn and Yahr (H&Y) stage, and cognitive, depressive, and psychotic symptoms.

The post Marijuana use is inversely associated with liver steatosis detected by transient elastography in the general United States population in NHANES 2017–2018: A cross-sectional study appeared first on Society of Cannabis Clinicians.

]]> The Effects of Long-Term Self-Dosing of Cannabidiol on Drowsiness, Testosterone Levels, and Liver Function https://www.cannabisclinicians.org/2023/04/02/the-effects-of-long-term-self-dosing-of-cannabidiol-on-drowsiness-testosterone-levels-and-liver-function/ Sun, 02 Apr 2023 14:17:40 +0000 https://www.cannabisclinicians.org/?p=28295 Previous research indicated that cannabidiol (CBD) may result in low levels of male total testosterone (TT), elevations in liver tests (LTs), and daytime drowsiness (DD). We investigated the prevalences of TT and LT in a large adult sample self-administering CBD and determined the effect self- dosing of CBD has on the severity of DD. Methods: Adult participants (18–75 years of age) who self-dose CBD orally for a minimum of 30 days were recruited for this decentralized observational study from companies that offer CBD products. Participants were sent their usual CBD regimen. A clinical study platform was used on a phone app to obtain consent and collect study data.

The post The Effects of Long-Term Self-Dosing of Cannabidiol on Drowsiness, Testosterone Levels, and Liver Function appeared first on Society of Cannabis Clinicians.

]]> Cannabidiol-associated hepatotoxicity: A systematic review and meta-analysis https://www.cannabisclinicians.org/2023/04/02/cannabidiol-associated-hepatotoxicity-a-systematic-review-and-meta-analysis/ Sun, 02 Apr 2023 13:27:18 +0000 https://www.cannabisclinicians.org/?p=28290 Inflammatory bowel diseases (IBDs) are chronic conditions of unknown cause or cure. Treatment seeks to reduce symptoms and induce and maintain remission. Many patients have turned to alternatives, such as cannabis, to alleviate living with IBD. This study reports the demographics, prevalence, and perception on cannabis use of patients attending an IBD clinic. Patients agreed to participate and completed an anonymous survey during their visit or online. Descriptive analysis, Fisher’s exact test, and Wilcoxon-Mann-Whitney rank-sum test were used. One hundred and sixty- two adults (85 males, 77 with CD) completed the survey. Sixty (37%) reported use of cannabis, of which 38 (63%) used it to relieve their IBD. A value of 77% reported low to moderate knowledge about cannabis, and 15% reported little to no knowledge. Among cannabis users, 48% had discussed use with their physician, but 88% said they would feel comfortable discussing medical cannabis for IBD. Most saw improvement of their symptoms (85.7%). A considerable number of patients with IBD use medical cannabis for their disease, unknown to their physician. The study reinforces the importance that physicians understand the role of cannabis in the treatment of IBD in order to appropriately counsel patients.

The post Cannabidiol-associated hepatotoxicity: A systematic review and meta-analysis appeared first on Society of Cannabis Clinicians.

]]> Cannabidiol markedly alleviates skin and liver fibrosis https://www.cannabisclinicians.org/2022/11/12/cannabidiol-markedly-alleviates-skin-and-liver-fibrosis/ Sat, 12 Nov 2022 14:33:52 +0000 https://www.cannabisclinicians.org/?p=27142 Cannabidiol (CBD) has been suggested as a potential therapy for inflammatory and fibrotic diseases. Cannabidiol was demonstrated to reduce alcohol-induced liver inflammation and steatosis but its specific activity on the fibrotic process was not investigated. Herein, the antifibrotic effects of cannabidiol in the skin were analysed in vitro using NIH-3T3 fibroblasts and human dermal fibroblasts and in vivo using the bleomycin-induced model of skin fibrosis. In a second model, non-alcoholic liver fibrosis was induced in mice by CCl4 exposure. Cannabidiol was administered daily, intraperitoneally in mice challenged with bleomycin and orally in CCl4 mice, and skin and liver fibrosis and inflammation were assessed by immunochemistry.

The post Cannabidiol markedly alleviates skin and liver fibrosis appeared first on Society of Cannabis Clinicians.

]]> Cannabis Use May Reduce Healthcare Utilization and Improve Hospital Outcomes in Patients with Cirrhosis https://www.cannabisclinicians.org/2020/11/12/cannabis-use-may-reduce-healthcare-utilization-and-improve-hospital-outcomes-in-patients-with-cirrhosis/ Thu, 12 Nov 2020 22:39:12 +0000 https://www.cannabisclinicians.org/?p=20552 Authors: Lindsay A. Sobotka, Khalid Mumtaz, Alice Hinton, Sean G. Kelly, Lanla F. Conteh, Anthony J. Michaels, A. James Hanje, Michael R. Wellnera Published in Annals of Hepatology November 2020...

The post Cannabis Use May Reduce Healthcare Utilization and Improve Hospital Outcomes in Patients with Cirrhosis appeared first on Society of Cannabis Clinicians.

]]> Cannabis use is associated with reduced prevalence of progressive stages of alcoholic liver disease https://www.cannabisclinicians.org/2020/11/03/cannabis-use-is-associated-with-reduced-prevalence-of-progressive-stages-of-alcoholic-liver-disease/ Tue, 03 Nov 2020 19:20:22 +0000 https://www.cannabisclinicians.org/?p=20460 Authors: Adeyinka C Adejumo, Tokunbo O Ajayi, Oluwole M Adegbala, Kelechi L Adejumo, Samson Alliu, Akintunde M Akinjero, Nnaemeka E Onyeakusi, Ogooluwa Ojelabi, Terence N Bukong Published in Liver International...

The post Cannabis use is associated with reduced prevalence of progressive stages of alcoholic liver disease appeared first on Society of Cannabis Clinicians.

]]> Cardiovascular pharmacology of cannabinoids. https://www.cannabisclinicians.org/2005/01/01/cardiovascular-pharmacology-of-cannabinoids/ Sat, 01 Jan 2005 22:48:55 +0000 https://www.cannabisclinicians.org/?p=14965 Authors: P. Pacher, S. Bátkai, G. Kunos
Handbook of Experimental Pharmacology, 2005
---
Cannabinoids and their synthetic and endogenous analogs affect a broad range of physiological functions, including cardiovascular variables, the most important component of their effect being profound hypotension. The mechanisms of the cardiovascular effects of cannabinoids in...

The post Cardiovascular pharmacology of cannabinoids. appeared first on Society of Cannabis Clinicians.

]]>